“We were impressed with the expertise and responsiveness of Cambridge Major, in particular their understanding of key project drivers and the regulatory environment around the compound,” confirmed Dr. Richard Vickers, Associate Director and Principal Investigator on the programme for Summit.
“We look forward to working with Summit to support an aggressive project development timeline,” commented Roger McDonald, European Business Development Director for CMLE.
“This is a Wellcome Trust-funded programme and it is important to have a clear, risk-managed focus on delivery to ensure Summit is able to achieve their milestones as quickly as possible. A key aspect of how we manage such first-time scale-up programmes is the ability to perform crystallization & polymorph screens in parallel with process chemistry. This approach is extremely efficient and manages risk very effectively.”
SMT 19969 is currently in formal preclinical development studies, the successful completion of which will enable it to enter human clinical trials. Summit anticipates submitting an application to regulatory authorities to commence clinical trials in Q3 2012.
About Cambridge Major Laboratories
Cambridge Major Laboratories, Inc. (CML) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The Company produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API), from early preclinical development to commercial manufacture. Operating from FDA inspected facilities in the US and Europe, CML is organized along five key Centers of Excellence including; Process Chemistry, GMP Manufacturing, Solid State Chemistry, Analytical Services, and Quality/Regulatory Compliance.
Learn more about CML by visiting www.c-mlabs.com.
About Summit
Summit is an Oxford, UK based drug discovery company with an innovative technology platform called Seglins for the discovery of new medicines, a portfolio of drug programme assets and a commercial strategy of signing multiple early-stage deals. Seglin™ technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches. Summit’s internal research is currently focussed in the high-value therapy areas and the Company will further exploit the technology’s wider potential through strategic alliances. Summit’s programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.
Further information is available at www.summitplc.com.
About The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
Learn more about Wellcome Trust by visting www.wellcome.ac.uk
Media Contacts: Mike Payne (CML) m.payne@c-mlabs.com 262-251-5044 ext.293 Roger McDonald (CMLE) roger.mcdonald@c-mlabs.nl Tel: +44 (0)1962 881615 Richard Pye, PhD (Summit) Tel: +44 (0)1235 443939
